We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03680560
Recruitment Status : Terminated (Business Reasons)
First Posted : September 21, 2018
Last Update Posted : March 31, 2020
Information provided by (Responsible Party):
Cogent Biosciences, Inc.

Brief Summary:
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.

Condition or disease Intervention/treatment Phase
Solid Tumor HER-2 Protein Overexpression Biological: ACTR T Cell Product Drug: Trastuzumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies
Actual Study Start Date : March 13, 2019
Actual Primary Completion Date : March 12, 2020
Actual Study Completion Date : March 12, 2020

Arm Intervention/treatment
Experimental: ACTR T cell product in combination with trastuzumab Biological: ACTR T Cell Product
Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)

Drug: Trastuzumab
monoclonal antibody targeting HER2

Primary Outcome Measures :
  1. Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values [ Time Frame: 42 days ]
  2. Determination of recommended phase 2 dose (RP2D) regimen [ Time Frame: 42 days ]
    Review of DLTs, maximum tolerated dose (MTD), incidence and severity of AEs and clinically significant abnormalities of laboratory values

Secondary Outcome Measures :
  1. Anti-tumor activity as measured by overall response rate (ORR) per iRECIST [ Time Frame: 52 weeks ]
  2. Anti-tumor activity as measured best overall response (BOR) [ Time Frame: 52 weeks ]
  3. Anti-tumor activity as measured by duration of response (DOR) [ Time Frame: 52 weeks ]
  4. Anti-tumor activity as measured by progression-free survival (PFS) [ Time Frame: 52 weeks ]
  5. Anti-tumor activity as measured by overall survival (OS) [ Time Frame: 52 weeks ]
  6. Assessment of persistence of ACTR as measured by flow cytometry [ Time Frame: 52 weeks ]
  7. Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR) [ Time Frame: 52 weeks ]
  8. Assessment of ACTR phenotype and function as measured by flow cytometry [ Time Frame: 52 weeks ]
  9. Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration [ Time Frame: 52 weeks ]
    Levels of inflammatory markers, cytokines/chemokines in blood

  10. Trastuzumab pharmacokinetics (PK) [ Time Frame: 52 weeks ]
    trastuzumab serum concentration, Area Under the Curve (AUC), trough levels

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent obtained prior to study procedures
  • Histologically-confirmed Her2 positive advanced solid tumor malignancy with documented disease progression during or immediately following the immediate prior therapy, or within 6 months of completing adjuvant therapy for subjects with breast cancer
  • Subjects must have previously received adequate standard therapy for treatment of their malignancy

    • For those with metastatic breast cancer, must have received HER2-directed therapy including trastuzumab, pertuzumab and ado-trastuzumab in any breast cancer disease setting
    • For those with advanced gastric cancer, adequate prior treatment with HER2-directed chemotherapy is required
  • At least 1 measurable lesion by iRECIST
  • Able to provide fresh tumor biopsy or archived block specimen taken since time of most recent anti-HER2 mAb-directed therapy
  • ECOG of 0 or 1
  • Life expectancy ≥ 6 months
  • LVEF ≥ 50% by MUGA or ECHO
  • Absolute neutrophil (ANC) count ≥ 1500/ µL
  • Platelet count ≥ 100,000/µL
  • Hemoglobin ≥ 9g/dL
  • Estimated GFR >30mL/min/1.73m2

Exclusion Criteria:

  • glioblastoma multiforme or other primary CNS tumors are excluded
  • clinically significant cardiac disease
  • clinically significant active infection
  • clinical history, prior diagnosis, or overt evidence of autoimmune disease
  • current use of more than 5mg/day of prednisone (or an equivalent glucocorticoid)
  • Prior treatment as follows:

    • prior cumulative doxorubicin dose greater than or equal to 300 mg/m^2 or equivalent
    • chemotherapy within 2 weeks of enrollment
    • external beam radiation within 2 weeks of enrollment (28 days if CNS-directed therapy)
    • any monoclonal antibody (mAb) or other protein therapeutic containing Fc-domains within 4 weeks of enrollment
    • pertuzumab within 4 months of enrollment
    • Experimental agents within 3 half-lives or 28 days prior to enrollment, whichever is shorter
    • allogeneic hematopoietic stem cell transplant (HSCT)
    • prior infusion of a genetically modified therapy
  • Pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03680560

Layout table for location information
United States, Connecticut
Yale Smilow Cancer Hospital
New Haven, Connecticut, United States, 06511
United States, Florida
Miami University Cancer Center
Miami, Florida, United States, 33136
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Tennessee
Sarah Cannon Research Institute/Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37203
United States, Texas
Baylor Scott & White Medical Center
Dallas, Texas, United States, 75201
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Cogent Biosciences, Inc.
Layout table for investigator information
Study Director: Glen Weiss, MD Cogent Biosciences, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Cogent Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT03680560    
Other Study ID Numbers: ATTCK-34-01
First Posted: September 21, 2018    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cogent Biosciences, Inc.:
T cell
T cell product
adoptive T cells
gene therapy
breast cancer
gastric cancer
gastro esophageal cancer
solid tumor
adenoid cystic carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents